A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis (P3-1.006)

Wakiro Sato; Eiichiro Amano; Tomoko Okamoto; Youwei Lin; Atsuko Katsumoto; Reiko Saika; Yuji Takahashi; Hideki Oi; Norimitsu Inoue; Sami Fam; Takashi Yamamura

doi:10.1212/wnl.0000000000216469

June 9, 2026Neurology

A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis (P3-1.006)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate the effectiveness and safety of ravulizumab in NMOSD patients who had inadequate responses to satralizumab.
Interim analysis of NMOSD patients switched from satralizumab to ravulizumab.
Assessment of efficacy based on patient responses.
Evaluation of safety and inflammatory biomarker effects.
Ravulizumab showed improved efficacy in managing NMOSD symptoms compared to prior treatment.
Safety profiles indicate a tolerable response with no significant adverse events reported.
Inflammatory biomarkers showed favorable changes post-treatment switch.

Implication

Real-world study assesses efficacy and safety of ravulizumab in NMOSD patients, suggesting potential benefits.

Abstract

To assess the efficacy and safety of ravulizumab and its effects on inflammatory biomarkers in NMOSD patients switched from satralizumab to ravulizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sato et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3b4faef96ed7f0562ef https://doi.org/10.1212/wnl.0000000000216469

View Full Paper

Ask AI

Bookmark

Share

A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis (P3-1.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

A Real-world Study of the Effectiveness and Safety of Ravulizumab in AQP4-Ab+ NMOSD Patients with Suboptimal Response to Satralizumab in Japan - Interim Analysis (P3-1.006)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading